Technology tamfitronics News in Brief Published: 14 October 2024 Nature Biotechnology volume42,page 1478 (2024)Cite this article The new bispecific drug ivonescimab has outperformed Mercks blockbuster PD-1 checkpoint inhibitor Keytruda (pembrolizumab) in a head-to-head clinical trial of non-small-cell lung cancer. The dual-action VEGFPD-1 antibody nearly doubled progression-free survival over the PD-1 blocker, according to phase 3 […]

Read More